{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:47:58Z","timestamp":1785908878436,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853976"],"award-info":[{"award-number":["853976"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmi.2026.05.024","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:03:35Z","timestamp":1780531415000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostatic tissue distribution of gepotidacin in patients undergoing prostatectomy: an ex vivo microdialysis and pharmacokinetic modelling study"],"prefix":"10.1016","author":[{"given":"Valentin","family":"al Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Aranzana-Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselm","family":"Jorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"W\u00f6lfl-Duchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Leutzendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Pracher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Kum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sanz","family":"Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Ping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Couet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.05.024_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000342653","article-title":"Acute bacterial prostatitis in humans: Current microbiological spectrum, sensitivity to antibiotics and clinical findings","volume":"89","author":"Nagy","year":"2012","journal-title":"Urol Int"},{"key":"10.1016\/j.cmi.2026.05.024_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00534-21","article-title":"Risk factors for relapse in acute bacterial prostatitis: The impact of antibiotic regimens","volume":"9","author":"Marquez-Algaba","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2026.05.024_bib3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.cmi.2026.05.024_bib4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2026.05.024_bib5","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","article-title":"Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: Genetic and biochemical evidence for well-balanced dual-targeting","volume":"10","author":"Oviatt","year":"2024","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.cmi.2026.05.024_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01525-22","article-title":"Antimicrobial activity of gepotidacin tested against Escherichia coli and Staphylococcus saprophyticus isolates causing urinary tract infections in medical centers worldwide (2019 to 2020)","volume":"67","author":"Arends","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.024_bib7","unstructured":"Shazad Mushtaq, Shazad Mushtaq, Anna Vickers, Zahra Sadouki, Michelle Cole, Helen Fifer, et al., In vitro activities of gepotidacin, a novel triazaacenaphthylene topoisomerase IV and DNA gyrase inhibitor, against Gram-negative bacteria and Staphylococcus saprophyticus. European Congress of Clinical Microbiology & Infectious Diseases, 15 April 2019 - P1849"},{"key":"10.1016\/j.cmi.2026.05.024_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.cmi.2026.05.024_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: Metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.024_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","article-title":"An automated sampling importance resampling procedure for estimating parameter uncertainty","volume":"44","author":"Dosne","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.cmi.2026.05.024_bib11","article-title":"FDA. BLUJEPA (gepotidacin) prescribing information. Silver Spring, MD: U.S","year":"2025","journal-title":"Food and Drug Administration"},{"key":"10.1016\/j.cmi.2026.05.024_bib12","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1023\/A:1011992125204","article-title":"Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method","volume":"15","author":"Bouw","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.cmi.2026.05.024_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0169-409X(00)00104-6","article-title":"Microdialysis in the study of drug transporters in the CNS","volume":"45","author":"Sawchuk","year":"2000","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cmi.2026.05.024_bib14","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1023\/A:1018906821725","article-title":"Microdialysis calibration using retrodialysis and zero-net flux: Application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus","volume":"10","author":"Wang","year":"1993","journal-title":"Pharm Res"},{"key":"10.1016\/j.cmi.2026.05.024_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01263-21","article-title":"Pharmacokinetics of oral formulations of gepotidacin (GSK2140944), a Triazaacenaphthylene bacterial type II topoisomerase inhibitor, in healthy adult and adolescent participants","volume":"66","author":"Barth","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.024_bib16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/bja\/62.6.674","article-title":"Antroduodenal motility, pH and gastric emptying during balanced anaesthesia: Comparison of pethidine and fentanyl","volume":"62","author":"Schurizek","year":"1989","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.cmi.2026.05.024_bib17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/00498254.2024.2343892","article-title":"Developmental stage and infection status may affect drug distribution in the prostate of rats","volume":"54","author":"Xu","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cmi.2026.05.024_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00005392-199502000-00076","article-title":"Antibiotic pharmacokinetics in the inflamed prostate","volume":"153","author":"Nickel","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.cmi.2026.05.024_bib19","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s12024-023-00709-z","article-title":"Postmortem redistribution of drugs: A literature review","volume":"20","author":"Abdelaal","year":"2024","journal-title":"Forensic Sci Med Pathol."},{"key":"10.1016\/j.cmi.2026.05.024_bib20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00216-015-9234-9","article-title":"Development of CT-guided biopsy sampling for time-dependent postmortem redistribution investigations in blood and alternative matrices\u2014proof of concept and application on two cases","volume":"408","author":"Staeheli","year":"2016","journal-title":"Anal Bioanal Chem."},{"key":"10.1016\/j.cmi.2026.05.024_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00296-25","article-title":"In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis, and Staphylococcus saprophyticus","volume":"69","author":"Hackel","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.024_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00468-17","article-title":"Gepotidacin (GSK2140944) in vitro activity against gram-positive and gram-negative bacteria","volume":"61","author":"Flamm","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.024_bib23","doi-asserted-by":"crossref","unstructured":"Kresken M., Wohlfarth E., Weikel C., Butler D., Pfeifer Y., Werner G. In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany. Journal of Antimicrobial Chemotherapy, Volume 78, Issue 2, February 2023, Pages 418\u2013422. https:\/\/doi.org\/10.1093\/jac\/dkac406.","DOI":"10.1093\/jac\/dkac406"},{"key":"10.1016\/j.cmi.2026.05.024_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00122-21","article-title":"Gepotidacin pharmacokinetics-pharmacodynamics against Escherichia coli in the one-compartment and hollow-fiber in vitro infection model systems","volume":"65","author":"VanScoy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.024_bib25","series-title":"Abhinav Kurumaddali. Pharmacokinetic and pharmacodynamic (PK\/PD) characterisation of gepotidacin against Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh infection model","author":"Jennifer Hoover","year":"2022"},{"key":"10.1016\/j.cmi.2026.05.024_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01492-21","article-title":"Dose selection for phase III clinical evaluation of gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections","volume":"66","author":"Scangarella-Oman","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.024_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02095-16","article-title":"Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections","volume":"61","author":"O'Riordan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.024_bib28","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): A phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.05.024_bib31","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0022-5347(17)36939-2","article-title":"Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography","volume":"148","author":"Inaba","year":"1992","journal-title":"J Urol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26002661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26002661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:09:11Z","timestamp":1785906551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26002661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"alternative-id":["S1198743X26002661"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.024","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostatic tissue distribution of gepotidacin in patients undergoing prostatectomy: an ex vivo microdialysis and pharmacokinetic modelling study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}